Convalescent Plasma Therapy for Covid-19 Patients at RSUP Dr. Wahidin Sudirohusodo Makassar

Abstract

Background : The use of convalescent plasma therapy (CPT) for COVID-19 patients based on the Plasma convalescent Therapy protocol recommended by the Plasma Convalescent Therapy Team of the Indonesian Ministry of Health Methods : Clinical trial study conducted from April -September 2020, in the group of COVID-19 patients who were treated with WHO standard therapy for COVID-19 combined with convalescent plasma administration. The results of clinical, radiological and laboratory monitoring were compared with the control group. The research consisted of 2 stages : The first stage was the search for donors: all donors were male, had no other comorbidities with Anti-SARS-CoV-2 IgG titer by ELISA method >20 COI. The second stage was to determine the recipients : adult COVID-19 patients (18-60 years) with moderate and severe criteria, according to WHO guidelines. COVID-19 patients undergo therapy in the Special Inpatient Installation (Isolation) or Intensive Care (ICU).Results: We got 8 potential donors from 200 people who recovered from covid-19, anti-SARS-CoV2 IgG levels was 28.38+5.4 COI. In the second stage, that received convalescent plasma therapy consisted of 4 patients moderate criteria and 4 patients severe criteria. There were 2 patients with severe criteria who died after Day+7 due to renal failure and secondary infection characterized by elevated procalcitonin levels. all patients with moderate criteria recovered. Laboratory results of hematology, hemostasis, and inflammatory markers improved before H+7, but radiological examination results improved after Day+7 discussion In this study, it seems that the effectiveness of giving CPT to moderate-grade patients gives better results, compared to control patients and COVID-19 patients with severe criteria. it is in accordance with several clinical trials in china ConclusionFrom this study, it can be concluded that convalescent plasma therapy can be recommended, especially in moderate-grade COVID-19 patients. Further studies on a larger scale are needed regarding the effectiveness and timing of convalescent plasma administration in mild-moderate COVID-19 patients.